~~<i id='BAD51923A5'><strike id='BAD51923A5'><tt id='BAD51923A5'><pre id='BAD51923A5'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：knowledge 2025-09-28 05:59:59 Page View：2

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Harvard scientists, with Google, unveil the most detailed brain map ever
Next article： Psychedelics group wrestles with new pharma identity

comprehensive

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Gut bacteria may contribute to kidney autoimmunity, study finds

AdobeRightnow,insideyourdigestivetract,therearetrillionsofbacteria,fungi,andvirusesthatformatinyuniv

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

SammyKimballforSTATAredrugpricesprotectedbytheConstitution?WillMedicareembraceAlzheimer’sdiseasetrea